JB Pharma witness 20% growth in August 2022: IQVIA
Our strategy to drive therapy and brand-focused expansion will continue to show results, especially in the domestic business.
Our strategy to drive therapy and brand-focused expansion will continue to show results, especially in the domestic business.
This newly launched institute will be the centre of excellence in the treatment of all cancers under a single roof.
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Phase 2 study evaluating an investigational weekly oral combination treatment regimen of islatravir and Gilead Sciences’ lenacapavir to resume with lower dose of islatravir
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial
Despite the technological advancements, there remains no alternative to blood and one unit of blood can save as many as three lives
Philips FetView will offer real-time, off cart remote patient management with access to data from any ultrasound system
Subscribe To Our Newsletter & Stay Updated